(Boursier.com) — The pharmaceutical biotechnology company Medesis Pharma will participate in the AAIC conference (Alzheimer’s Association International Conference). From July 16-20, 2023 in Amsterdam, the Alzheimer’s Association International Conference is the largest and most influential international meeting dedicated to advancing the science of dementia. Each year, the AAIC brings together leading researchers and clinicians in the field of Alzheimer’s to share the latest discoveries that will lead to the development of methods for the prevention, treatment and improved diagnosis of Alzheimer’s disease.
Solène Guilliot, Medical Director & R&D Director of Medesis Pharma, will be present to meet the main players in the field and present a scientific poster describing the design of the ongoing Phase II study, which aims to demonstrate the effect of NanoLithium on behavioral and psychological symptoms in patients with mild to severe Alzheimer’s disease and to identify a potential disease-modifying effect.
The study on NanoLithium, a drug candidate from Medesis Pharma, involves 68 patients with Alzheimer’s disease. It is in progress in 8 university hospital centers (CHU of Montpellier, Toulouse, Paris, Lille, Lyon, Limoges, Marseille and Strasbourg). The first patients were included in June 2022 in Toulouse, and the other university hospitals began inclusions from November.
Currently more than half of the patients are included in the study. Recruitment should end in the fall of 2023, with the prospect of the first clinical results in the 1st quarter of 2024.
©2023 Boursier.com